Clinical trials
Recurrent or Metastatic Cervical Cancer clinical trials
Below are recruiting recurrent or metastatic cervical cancer clinical trials, each written for real people, not researchers. We’re tracking 3,920 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04761328Recruiting
Study fear of cancer coming back and stopping immunotherapy
This study looks at fear of cancer coming back and how people feel about stopping immunotherapy (cancer treatment that helps the immune system). You may be able to join if you’re an adult with a cancer history that included immunotherapy, and if you can safely participate.
Pittsburgh, PennsylvaniaAges 21 years+ - NCT04765514RecruitingPhase 2
Chemo with radiation versus chemo alone for older brain tumor patients
This trial compares two standard treatments for newly diagnosed glioblastoma (a serious brain cancer) in older and frail patients: chemo plus radiation versus chemo alone. It may help determine which approach works best and is safest for people in your age and health group.
Calgary, AlbertaAges 65 years+ - NCT04772768Recruiting
Checking problems in vein bypass grafts in people with recurring chest pain
This study looks at how vein bypass grafts are working over time in people who had heart bypass surgery and now have recurring angina (chest discomfort). It may help doctors better understand why symptoms come back and how the heart and grafts change.
AmsterdamAges 18–90 - NCT04778956RecruitingPhase 3
Toripalimab plus surgery vs surgery alone for recurring throat cancer
This trial tests whether adding toripalimab (an immune therapy) to surgery helps people with recurrent nasopharyngeal cancer live longer or control the cancer better than surgery alone. You may qualify if your recurrence can be fully removed by surgery and it came back after a certain amount of time.
Guangzhou, GuangdongAges 18–70 - NCT04797767RecruitingPhase 1/Phase 2
Venetoclax plus CLAG-M for high-risk AML
This trial studies venetoclax combined with CLAG-M chemotherapy to treat adults with high-risk acute myeloid leukemia (AML) or related high-grade blood cancers. It aims to improve control of the disease, especially in people whose AML is considered high risk.
Seattle, WashingtonAges 18 years+ - NCT04823403RecruitingPhase 1
Targeted liver delivery of immunotherapy for advanced liver cancer
This early-phase study tests how well giving ipilimumab directly into the liver (via an artery) and nivolumab through a vein works for advanced hepatocellular carcinoma (liver cancer). It is for people whose cancer cannot be removed with surgery or treated with a transplant, especially after standard treatment failed or wasn’t tolerated.
VillejuifAges 18 years+ - NCT04830267RecruitingPhase 2
Camrelizumab plus focused radiation for recurrent metastatic nasopharyngeal cancer
This Phase 2 trial studies whether adding camrelizumab (an immune medicine) to stereotactic body radiation (focused, high-precision radiation) helps people with recurrent or metastatic nasopharyngeal cancer. It aims to improve control of the cancer (and may use blood EBV levels to help track response).
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT04849130Recruiting
Compare two surgical MPFL techniques for kneecap dislocation
This trial compares two ways surgeons rebuild a key ligament (the MPFL) to help stop recurrent kneecap dislocations. It may help you by checking which technique works better for stability and recovery.
BaselAges 14 years+ - NCT04858256RecruitingPhase 2
Pacritinib for relapsed or resistant T-cell blood cancers
This Phase 2 trial studies pacritinib, an oral medicine, for T-cell lymphoma/leukemia that has come back or did not respond to prior treatment. It aims to see how well pacritinib can control the cancer and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT04863950RecruitingPhase 2
Imipramine plus lomustine for recurrent glioblastoma
This study tests whether combining imipramine (a medicine used for mood and sometimes nerve pain) with lomustine (a chemotherapy) can slow or treat recurrent glioblastoma that has come back after standard radiation and temozolomide. It is mainly for adults who are well enough to travel through treatment and monitoring scans and blood tests.
San Antonio, TexasAges Any age - NCT04871607RecruitingPhase 2
Yttrium antibody plus chemotherapy for hard-to-treat Hodgkin lymphoma
This trial studies a targeted antibody therapy with yttrium, combined with intensive chemotherapy, for adults whose Hodgkin lymphoma did not respond well or came back. It may help by delivering cancer-killing radiation directly to lymphoma cells and preparing the body for treatment after transplant conditioning.
Duarte, CaliforniaAges 18 years+ - NCT04900623RecruitingPhase 2
Using HPV blood test to guide treatment for HPV throat cancer
This Phase 2 study tests a “risk-adapted” treatment plan for HPV-related throat cancer, using an HPV DNA blood test to help decide how treatment is done. If your baseline blood test shows detectable HPV DNA, the study may help tailor therapy to your risk and potentially improve outcomes while limiting unnecessary treatment.
Boston, MassachusettsAges 22 years+ - NCT04902443RecruitingPhase 1
Pomalidomide plus nivolumab for virus-related cancers
This trial studies pomalidomide plus nivolumab in people with cancers linked to certain viruses (or hepatitis B/C). It may help the immune system fight the cancer when the disease has returned, progressed, or can’t be fully treated with standard options.
Bethesda, MarylandAges 18–99 - NCT04902937Recruiting
Testing how added radiation may work by immune and tumor markers
This study looks at people with non-metastatic invasive breast cancer who are getting curative breast surgery followed by planned radiation (sometimes with other anti-cancer medicines). Researchers want to understand whether a patient’s age and certain immune/tumor blood features can predict how well radiation helps.
JenaAges 18 years+ - NCT04903899RecruitingPhase 2
Lutetium-DOTATATE for relapsed or hard-to-treat neuroblastoma in children
This Phase 2 trial tests a targeted radioactive medicine called 177Lutetium-DOTATATE in children with high-risk neuroblastoma that has returned or did not respond to treatment. It’s designed for tumors that show strong uptake on special scans, which may help the medicine find and treat cancer cells.
Copenhagen, CopenhagenAges 1.5 years+ - NCT04905810RecruitingPhase 2
Azacitidine or decitabine plus venetoclax for AML after prior failure
This trial studies whether adding venetoclax to either azacitidine or decitabine can treat acute myeloid leukemia (AML) when earlier “hypomethylating” treatment has stopped working. You might be a candidate if you’ve already tried azacitidine or decitabine for a related blood condition and it failed, and you meet the health-safety limits.
Clovis, CaliforniaAges 18 years+ - NCT04923126RecruitingPhase 1/Phase 2
Mirdametinib for children with low-grade brain tumors
This Phase 1/2 study tests mirdametinib, a targeted medicine, in children and young adults with low-grade glioma (a slower-growing brain tumor). It aims to find the best dose and see how well the treatment works, especially for tumors with certain “MAPK pathway” changes.
Memphis, TennesseeAges 2–24 - NCT04925154Recruiting
Study of decision-making for rectal cancer treatment
This study asks people newly diagnosed with rectal cancer about how they choose between treatment benefits and quality of life. It uses questionnaires to understand what tradeoffs matter to patients so care discussions can be improved.
Montreal, QuebecAges 18 years+ - NCT04927897Recruiting
Testing where to aim extra rectal radiation before surgery
This trial tests the best place to target an “extra boost” of radiation inside the rectum for certain rectal cancer patients. It may help guide more precise treatment planning before they have total mesorectal excision (TME) surgery.
Maastricht, LimburgAges 18 years+ - NCT07428616RecruitingPhase 2
Study of Zanzalintinib for recurring meningioma
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT07243002Recruiting
Patient outcomes with ribociclib or abemaciclib for early breast cancer
This study looks at how women and men with stage II or III HR+ HER2- breast cancer do when they start treatment with ribociclib or abemaciclib (combined with hormone therapy) after surgery. Researchers want to understand real-world experiences and results.
LondonAges 18 years+ - NCT04939051RecruitingPhase 2
Obeticholic acid to prevent Barrett’s esophagus worsening
This Phase 2 trial tests whether obeticholic acid (a medicine) can help stop Barrett’s esophagus from getting worse. You must already be taking acid-suppressing medicine and have non-cancer Barrett’s changes, and the study checks safety and whether the lining improves or stays stable.
Kansas City, KansasAges 18 years+ - NCT04969835RecruitingPhase 1
Safety and early response study of AVA6000 for solid tumors
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
New York, New YorkAges 18 years+ - NCT04977375RecruitingPhase 1/Phase 2
Anti–PD-1 treatment plus focused radiation for recurrent glioblastoma
This trial tests a cancer-immunotherapy medicine (an anti–PD-1 antibody, similar to pembrolizumab) combined with precisely targeted radiation to treat glioblastoma that has come back or progressed. It may help your immune system recognize and attack the tumor while the radiation targets the cancer.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic cervical cancer?
- Yes. Clin2 currently lists 3,920 recruiting recurrent or metastatic cervical cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic cervical cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic cervical cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.